ethyl 3-(6-bromopyridin-2-yl)propanoate | 1198615-09-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 3-(6-bromopyridin-2-yl)propanoate
• 英文别名: ethyl 3-(6-bromopyridin-2-yl)propionate；Ethyl 3-(6-bromopyridin-2-yl)propanoate
• CAS: 1198615-09-6
• 化学式: C₁₀H₁₂BrNO₂
• 分子量: 258.115
• InChiKey: ISRODJQFNBKQEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-(6-bromopyridin-2-yl)propanoate 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium tetrahydroborate 、 copper(l) iodide 、 18-冠醚-6 、 偶氮二甲酸二异丙酯 、 氢气 、 nickel(II) acetate tetrahydrate 、 双(三甲基硅烷基)氨基钾 、 二异丁基氢化铝 、 乙二胺 、 二异丙胺 、 三苯基膦 、 sodium hydroxide 、 lithium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 二氯甲烷 、 水 、 苯 为溶剂， 反应 14.17h， 生成
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Neopeltolide and Analogs

  摘要：

  The synthesis of neopeltolide analogues that contain variations in the oxazole-containing side chain and in the macrolide core are reported along with the GI(50) values for these compounds against MCF-7, HCT-116, and p53 knockout HCT-116 cell lines. Although biological activity is sensitive to changes in the macrocycle and the side chain, several analogues displayed GI(50) values of <25 nM. Neopeltolide and several of the more potent analogues were significantly less potent against p53 knockout cells, suggesting that p53 plays an auxiliary role in the activity of these compounds.

  DOI：

  10.1021/jo2023685
• 作为产物：
  描述：

  6-溴吡啶-2-甲醛 在 sodium tetrahydroborate 、 sodium hydride 、 copper(l) chloride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 0.5h， 生成 ethyl 3-(6-bromopyridin-2-yl)propanoate
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Neopeltolide and Analogs

  摘要：

  The synthesis of neopeltolide analogues that contain variations in the oxazole-containing side chain and in the macrolide core are reported along with the GI(50) values for these compounds against MCF-7, HCT-116, and p53 knockout HCT-116 cell lines. Although biological activity is sensitive to changes in the macrocycle and the side chain, several analogues displayed GI(50) values of <25 nM. Neopeltolide and several of the more potent analogues were significantly less potent against p53 knockout cells, suggesting that p53 plays an auxiliary role in the activity of these compounds.

  DOI：

  10.1021/jo2023685

文献信息

• [EN] SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS<br/>[FR] INHIBITEURS À PYRIDINE SUBSTITUÉE DE LA TYROSINE KINASE DE LA RATE (SYK)
  申请人：MERCK SHARP & DOHME

  公开号：WO2013192098A1

  公开（公告）日：2013-12-27

  The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy,Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  该发明提供了Formula (I)中的某些取代吡啶化合物或其药用可接受的盐，其中R1、R2、R3、R4、Rcy、Cy和t如本文所定义。该发明还提供了包括这些化合物的药物组合物，以及利用这些化合物治疗由脾酪氨酸激酶（Syk）介导的疾病或症状的方法。
• SULFONAMIDE COMPOUNDS AND THE USE
  申请人：OGAWA Masami

  公开号：US20100022601A1

  公开（公告）日：2010-01-28

  The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and/or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are useful as an effective component of a medicament for the prophylaxis and/or treatment of bone disorders such as osteoporosis, bone fracture, hypoparathyroidism and the like.

  提供以下式(1)的磺酰胺化合物，可用作预防或治疗包括骨质疏松症等骨疾病的CaSR拮抗剂的有效成分。这些化合物具有促进PTH分泌的卓越活性。此外，这些化合物还用作预防或治疗骨质疏松症、骨折、低甲状旁腺功能等骨疾病药物的有效成分。
• SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150148327A1

  公开（公告）日：2015-05-28

  The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R cy , C y , and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  本发明提供了以下公式（I）的某些取代吡啶或其药学上可接受的盐，其中R1，R2，R3，R4，Rcy，Cy和t如本文所定义。 本发明还提供了包含这种化合物的制药组合物，并且提供了使用这些化合物治疗由脾酪氨酸激酶（Syk）激酶介导的疾病或病症的方法。
• Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US09376418B2

  公开（公告）日：2016-06-28

  The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  该发明提供了某些式(I)的取代吡啶或其药学上可接受的盐，其中R1、R2、R3、R4、Rcy、Cy和t的定义如本文所述。该发明还提供了包含这些化合物的药物组合物，并使用这些化合物治疗由脾酪氨酸激酶（Syk）介导的疾病或病状的方法。
• SULFONAMIDE COMPOUND AND APPLICATION THEREOF
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP2292592A1

  公开（公告）日：2011-03-09

  The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and/or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are useful as an effective component of a medicament for the prophylaxis and/or treatment of bone disorders such as osteoporosis, bone fracture, hypoparathyroidism and the like.

  本发明提供了具有下式（1）的砜酰胺化合物，可用作预防和/或治疗骨质疏松症等骨病的 CaSR 拮抗剂的有效成分。这些化合物具有良好的促进 PTH 分泌的活性。此外，这些化合物还可作为预防和/或治疗骨质疏松症、骨折、甲状旁腺功能减退症等骨病的药物的有效成分。